Latest filing published 30 Jul 2026 for Greenwich LifeSciences, Inc., €8,051. Read the official filing
Across 32 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Snehal Patel (chief executive) discloses dealings in Greenwich LifeSciences, Inc. to SEC (Form 4). Between 29 September 2020 and 29 July 2026, the trades on record add up to 94 filings.
The open-market record is one-sided, with 84 purchases worth €6.5M and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 10 option exercises. 2026 to date brings 9 purchases and no sales.
In size, the median ticket on the buying side is €32k. Relative to company size, the median is 0.0077% of market cap (5 purchases with a known value). 34 out of 84 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
The record was last updated on 30 July 2026 with an open-market purchase (€18k) in Greenwich LifeSciences, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 81 declarations